Induction of drug transporters alters disposition of risperidone - A study in mice

Pharmaceutics

Volumn 2, Issue 2, 2010, Pages 258-274

  Holthoewer, David ^a   Hiemke, Christoph ^a   Schmitt, Ulrich ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

9 hydroxyrisperidone; Antipsychotics; Disposition; Drug transporter; P glycoprotein; Risperidone

Indexed keywords

16ALPHA CYANOPREGNENOLONE; DEXAMETHASONE; GLYCOPROTEIN P; PALIPERIDONE; RIFAMPICIN; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLITE; MOUSE; NONHUMAN;

EID: 79952175442     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics2020258     Document Type: Article

References (32)

1. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42, 1007-1017.
2. Schinkel, A.H.; Mayer, U.; Wagenaar, E.; Mol, C.A.; van Deemter, L.; Smit, J.J.; van der Valk, M.A.; Voordouw, A.C.; Spits, H.; van Tellingen, O.; Zijlmans, J.M.; Fibbe, W.E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P- glycoprotein. Proc. Natl. Acad. Sci. USA 1997, 94, 4028-4033.
3. Bauer, B.; Hartz, A.; Fricker, G.; Miller, D. Modulation of P-glycoprotein transport function at the blood-brain barrier. Exp. Biol. Med. 2005, 230, 118-127.
4. Abou El-Ela, A.; Härtter, S.; Schmitt, U.; Hiemke, C.; Spahn-Langguth, H.; Langguth, P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds- implications for pharmacokinetics of selected substrates. J. Pharm. Pharmacol. 2004, 56, 1-9.
5. Boulton, D.W.; DeVane, C.L.; Liston, H.L.; Markowitz, J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002, 71, 163-169.
6. Doan, K.M.M.; Humphreys, J.E.; Webster, L.O.; Wring, S.A.; Shampine, L.J.; Serabjit-Singh, C.J.; Adkinson, K.K.; Polli, J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037.
7. Doran, A.; Obach, S.; Smith, B.J.; Hosea, N.A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L.M.; Gibbs, J.P.; Gibbs, M.A.; Hatch, H.; Hop, C.; Kasman, I.N.; LaPerle, J.; Liu, J.H.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F.M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D.K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; van Deusen, J.W.; Venkatakrishnan, K.; Walens, G.; Wang, E.Q.; Wong, D.; Yasgar, A.S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1a/1b knockout mouse model. Drug Metab. Dispos. 2005, 33, 165-174.
8. Uhr, M.; Grauer, M.T.; Holsboer, F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1 ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 2003, 54, 840-846.
9. Kirschbaum, K.M.; Henken, S.; Hiemke, C.; Schmitt, U. Pharmacodynamic consequences of P- glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res. 2008, 188, 298-303.
10. Fang, J.; Bourin, M.; Baker, G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359, 147-151.
11. Martignoni, M.; Groothuis, G.M.M.; de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006, 2, 875-894.
12. Bauer, B.; Hartz, A.M.S.; Fricker, G.; Miller, D.S. Pregnane X receptor up-regulation of P- glycoprotein expression and transport function at the blood-brain-barrier. Mol. Pharmacol. 2004, 66, 413-419.
13. Kageyama, M.; Fukushima, K.; Togawa, T.; Fujimoto, K.; Taki, M.; Nishimura, A.; Ito, Y.; Sugioka, N.; Shibata, N.; Takada, K. Relationship between excretion clearance of rhodamine 123 and p-glycoprotein (P-gp) expression induced by representative P-gp inducers. Biol. Pharm. Bull. 2006, 29, 779-784.
14. Medori, R.; Mannaert, E.; Gruender, G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 2005, 16, 233-240.
15. Nyberg, S.; Dahl, M.J.; Halldin, C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 1995, 119, 345-348.
16. Gunes, A.; Spina, E.; Dahl, M.L.; Scordo, M.G. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther. Drug Monit. 2008, 30, 628-633.
17. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: A key role of xenobiotic metabolism. Endocr. Rev. 2002, 23, 687-702.
18. Kim, K.A.; Park, P.W.; Liu, K.H.; Kim, K.B.; Lee, H.J.; Shin, J.K.; Park, J.Y. Effect of rifampicin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J. Clin. Pharmacol. 2008, 48, 66-72.
19. Sonoda, J.; Rosenfeld, J.M.; Xu, L.; Evans, R.M.; Xie, W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr. Drug Metab. 2003, 4, 59-72.
20. Teng, S.; Jekerle, V.; Piquette-Miller, M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 2003, 31, 1296-1299.
21. Breedveld, P.; Beijnen, J.S.; Schellens, J.H.M. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 2006, 27, 17-24.
22. Hoffmann, K.; Löscher, W. Upregulation of brain expression of P-glycoprotein in MRP2- deficient TR-rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007, 48, 631-645.
23. Kast, H.R.; Goodwin, B.; Tarr, P.T.; Jones, S.A.; Anisfeld, A.M.; Stoltz, C.M.; Tontonoz, P.; Kliewer, S.; Willson, T.M.; Edwards, P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277, 2908-2915.
24. Köhle, C.; Bock, K.W. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol. 2009, 77, 689-699.
25. Narang, V.S.; Fraga, C.; Kumar, N.; Shen, J.; Throm, S.; Stewart, C.F.; Maters, C.M. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am. J. Physiol. Cell Physiol. 2008, 295, 440-450.
26. Matheny, C.J.; Ali, R.Y.; Yang, X.; Pollack, G.M. Effect of prototypical inducing agents on P- glycoprotein and CYP3A4 expression in mouse tissues. Drug Metab. Dispos. 2004, 32, 1008-1014.
27. Cheng, X.; Klaassen C.D.; Regulation of mRNA expression of xenobiotic transporters by the pregnane X receptor in mouse liver, kidney, and intestine. Drug Metab. Dispos. 2006, 34, 1863-1867.
28. Guzelian, J.; Barwick, J.L.; Hunter, L.; Phang, T.L.; Quattrochi, L.C.; Guzelian, P.S. Identification of genes controlled by the pregnane X receptor by microarray analysis of mRNAs from pregnenolone16α-carbonitrile- treated rats. Toxicol Sci. 2006, 94, 379-387.
29. Martin, P.; Riley, R.; Thompson, P.; Williams, D.; Back, D.; Owen, A. Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. Acta Pharmacol. Sin. 2010, 31, 51-65.
30. Yadav, S.; Dhawan, A.; Seth, P.K.; Singh, R.L.; Parmar, D. Cytochrome P4503A: Evidence for mRNA expression and catalytic activity in rat brain. Mol. Cell. Biochem. 2006, 287, 91-99.
31. Kirn, R.B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M.F.; Dempsey, P.J.; Roden, M.M.; Belas, F.; Chaudhary, A.K.; Roden, D.M.; Wood, A.J.J.; Wilkinson, G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16, 408-414.
32. Xu, C.; Li, Y.; Kong, A. Induction of phase I, II and III drug metabolism/ transport by xenobiotics. Arch. Pharm. Res. 2005, 28, 249-268.